ExpreS2ion Biotech Holding AB Share Price Nasdaq Stockholm
Equities
SE0008348262
Pharmaceuticals
Sales 2024 * | 8M 758K 58.37M | Sales 2025 * | 8M 758K 58.37M | Capitalization | 85.3M 8.08M 622M |
---|---|---|---|---|---|
Net income 2024 * | -25M -2.37M -182M | Net income 2025 * | -37M -3.51M -270M | EV / Sales 2024 * | 3.78 x |
Net cash position 2024 * | 55.05M 5.22M 402M | Net cash position 2025 * | 14.16M 1.34M 103M | EV / Sales 2025 * | 8.89 x |
P/E ratio 2024 * |
-2.66
x | P/E ratio 2025 * |
-1.82
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 100% |
Managers | Title | Age | Since |
---|---|---|---|
Bent Frandsen
CEO | Chief Executive Officer | - | 31/12/15 |
Keith Alexander
DFI | Director of Finance/CFO | 48 | 30/09/20 |
Max M. Søgaard
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jakob Knudsen
BRD | Director/Board Member | 56 | 31/03/17 |
Karin Garre
BRD | Director/Board Member | 67 | 25/05/21 |
Martin Jensen
FOU | Founder | 64 | 31/12/09 |
1st Jan change | Capi. | |
---|---|---|
+8.54% | 100B | |
+11.97% | 43.89B | |
-11.76% | 33.24B | |
+80.16% | 29.36B | |
-12.20% | 16.08B | |
+4.00% | 14.68B | |
-1.90% | 12.87B | |
+178.17% | 10.55B | |
+3.52% | 8.83B |